Share Price and Basic Stock Data
Last Updated: January 9, 2026, 2:45 am
| PEG Ratio | 0.81 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dr Reddy’s Laboratories Ltd reported a revenue of ₹24,670 Cr for the fiscal year ending March 2023, which marked a substantial increase from ₹21,545 Cr in the previous year. The company’s sales have shown a consistent upward trajectory, with a year-on-year growth of approximately 10% from March 2022 to March 2023. As per the quarterly data, sales rose from ₹6,332 Cr in September 2022 to ₹6,903 Cr in September 2023, highlighting a steady demand for its pharmaceutical products. The trailing twelve months (TTM) sales stood at ₹34,310 Cr, indicating strong performance. The company expects to continue this growth, with forecasts indicating sales reaching ₹32,644 Cr for FY 2025. It is essential to note that Dr Reddy’s has successfully navigated various market dynamics, positioning itself favorably within the highly competitive pharmaceutical sector. The company’s strategic initiatives and product launches have contributed to its robust revenue growth, showcasing its resilience in an evolving market landscape.
Profitability and Efficiency Metrics
Dr Reddy’s Laboratories demonstrated impressive profitability metrics, with a reported net profit of ₹5,738 Cr for the fiscal year ending March 2025, reflecting a significant increase from ₹4,507 Cr in March 2023. The net profit margin was recorded at 17.47%, indicative of strong operational efficiency compared to industry averages. Operating profit margin (OPM) stood at 26% for FY 2025, underscoring the company’s ability to manage costs effectively while driving revenue. Additionally, the company’s return on equity (ROE) was reported at 18%, and return on capital employed (ROCE) at 23%, both of which are favorable compared to typical sector norms. The interest coverage ratio (ICR) stood at a robust 34.09x, indicating that Dr Reddy’s can comfortably meet its interest obligations, a critical factor for maintaining investor confidence. These metrics collectively illustrate the company’s strong operational efficiency and profitability, enhancing its attractiveness to both investors and stakeholders.
Balance Sheet Strength and Financial Ratios
Dr Reddy’s Laboratories maintains a solid balance sheet, with total assets reported at ₹54,373 Cr as of September 2025, up from ₹48,023 Cr in March 2025. The company’s reserves have increased significantly, reaching ₹35,930 Cr, reflecting prudent financial management and reinvestment into the business. Borrowings stood at ₹5,854 Cr, maintaining a low debt-to-equity ratio of 0.12, which is considered favorable in the pharmaceutical industry. The current ratio was reported at 1.92, indicating adequate liquidity to cover short-term obligations. The company’s price-to-book value (P/BV) ratio was 2.84x, suggesting that the stock is reasonably valued relative to its book value. Overall, these financial ratios highlight Dr Reddy’s robust financial health, positioning it well for future growth while minimizing financial risk.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dr Reddy’s Laboratories reflects a diverse ownership structure, with promoters holding 26.64% of the stake, while Foreign Institutional Investors (FIIs) own 24.69%, and Domestic Institutional Investors (DIIs) hold 27.99%. The public holds 20.45%, indicating a balanced distribution among various investor categories. Notably, the DII ownership has shown an upward trend, increasing from 21.04% in September 2023 to 27.99% in September 2025, suggesting growing institutional confidence in the company’s prospects. The number of shareholders has also risen to 4,49,216, indicating increased retail interest. This diverse ownership structure enhances corporate governance and aligns the interests of various stakeholders. The stability in promoter shareholding coupled with increasing institutional investment signifies a strong endorsement of Dr Reddy’s strategic direction and operational performance.
Outlook, Risks, and Final Insight
Looking ahead, Dr Reddy’s Laboratories is well-positioned to capitalize on the growing demand for pharmaceuticals, particularly in emerging markets. However, the company faces certain risks, including regulatory challenges that can impact product approvals and potential pricing pressures in key markets. Furthermore, the increasing competition in the generic drug space could affect market share and margins. Operationally, the company’s ability to innovate and maintain its product pipeline will be crucial for sustaining growth. On the other hand, Dr Reddy’s robust financial performance, strong balance sheet, and effective cost management strategies provide a solid foundation for navigating these challenges. If the company continues to execute its strategic initiatives effectively, it could enhance its market position and deliver sustainable returns to its shareholders, making it an attractive proposition for long-term investors.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 210/84.3 | 28.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,407 Cr. | 404 | 479/192 | 91.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.0 Cr. | 39.6 | 41.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,548.28 Cr | 1,144.26 | 53.57 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,332 | 6,790 | 6,315 | 6,758 | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 |
| Expenses | 4,433 | 4,851 | 4,781 | 4,696 | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 |
| Operating Profit | 1,899 | 1,939 | 1,534 | 2,062 | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 |
| OPM % | 30% | 29% | 24% | 31% | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% |
| Other Income | 55 | 65 | 146 | 178 | 319 | 219 | 201 | 193 | 314 | 154 | 528 | 290 | 330 |
| Interest | 31 | 42 | 35 | 37 | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 |
| Depreciation | 309 | 324 | 316 | 353 | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 |
| Profit before tax | 1,614 | 1,638 | 1,329 | 1,850 | 1,917 | 1,829 | 1,605 | 1,883 | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 |
| Tax % | 31% | 24% | 28% | 24% | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% |
| Net Profit | 1,114 | 1,244 | 960 | 1,405 | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 |
| EPS in Rs | 13.39 | 14.94 | 11.53 | 16.87 | 17.77 | 16.56 | 15.70 | 16.69 | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 |
Last Updated: January 1, 2026, 10:04 pm
Below is a detailed analysis of the quarterly data for Dr Reddys Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 8,828.00 Cr.. The value appears strong and on an upward trend. It has increased from 8,572.00 Cr. (Jun 2025) to 8,828.00 Cr., marking an increase of 256.00 Cr..
- For Expenses, as of Sep 2025, the value is 6,818.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6,398.00 Cr. (Jun 2025) to 6,818.00 Cr., marking an increase of 420.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 2,010.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,174.00 Cr. (Jun 2025) to 2,010.00 Cr., marking a decrease of 164.00 Cr..
- For OPM %, as of Sep 2025, the value is 23.00%. The value appears to be declining and may need further review. It has decreased from 25.00% (Jun 2025) to 23.00%, marking a decrease of 2.00%.
- For Other Income, as of Sep 2025, the value is 330.00 Cr.. The value appears strong and on an upward trend. It has increased from 290.00 Cr. (Jun 2025) to 330.00 Cr., marking an increase of 40.00 Cr..
- For Interest, as of Sep 2025, the value is 91.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 83.00 Cr. (Jun 2025) to 91.00 Cr., marking an increase of 8.00 Cr..
- For Depreciation, as of Sep 2025, the value is 505.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 476.00 Cr. (Jun 2025) to 505.00 Cr., marking an increase of 29.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 1,745.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,905.00 Cr. (Jun 2025) to 1,745.00 Cr., marking a decrease of 160.00 Cr..
- For Tax %, as of Sep 2025, the value is 23.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 23.00%, marking a decrease of 3.00%.
- For Net Profit, as of Sep 2025, the value is 1,337.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1,410.00 Cr. (Jun 2025) to 1,337.00 Cr., marking a decrease of 73.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 16.14. The value appears to be declining and may need further review. It has decreased from 16.99 (Jun 2025) to 16.14, marking a decrease of 0.85.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:26 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13,415 | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 34,310 |
| Expenses | 10,164 | 11,515 | 11,983 | 11,724 | 11,930 | 12,270 | 15,040 | 15,173 | 17,778 | 18,200 | 20,078 | 24,097 | 25,856 |
| Operating Profit | 3,251 | 3,508 | 3,585 | 2,472 | 2,351 | 3,178 | 2,477 | 3,874 | 3,768 | 6,470 | 7,933 | 8,547 | 8,454 |
| OPM % | 24% | 23% | 23% | 17% | 16% | 21% | 14% | 20% | 17% | 26% | 28% | 26% | 25% |
| Other Income | 170 | 260 | 295 | 172 | 155 | 381 | 670 | 335 | 555 | 971 | 909 | 1,119 | 1,303 |
| Interest | 127 | 108 | 83 | 63 | 79 | 89 | 98 | 97 | 96 | 143 | 171 | 283 | 321 |
| Depreciation | 648 | 760 | 939 | 1,027 | 1,077 | 1,135 | 1,163 | 1,229 | 1,165 | 1,250 | 1,470 | 1,704 | 1,907 |
| Profit before tax | 2,646 | 2,900 | 2,859 | 1,554 | 1,350 | 2,336 | 1,886 | 2,884 | 3,061 | 6,048 | 7,201 | 7,680 | 7,529 |
| Tax % | 26% | 19% | 26% | 19% | 32% | 17% | -7% | 32% | 29% | 25% | 23% | 25% | |
| Net Profit | 1,963 | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,182 | 4,507 | 5,578 | 5,725 | 5,738 |
| EPS in Rs | 23.08 | 27.43 | 24.98 | 15.59 | 11.41 | 23.49 | 24.38 | 23.47 | 26.23 | 54.14 | 66.87 | 67.77 | 69.16 |
| Dividend Payout % | 16% | 15% | 16% | 26% | 35% | 17% | 21% | 21% | 23% | 15% | 12% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 19.00% | -8.78% | -39.37% | -26.70% | 105.91% | 3.90% | -3.65% | 11.78% | 106.55% | 23.76% | 2.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | -27.78% | -30.60% | 12.67% | 132.62% | -102.02% | -7.55% | 15.44% | 94.77% | -82.79% | -21.13% |
Dr Reddys Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
Last Updated: September 5, 2025, 3:10 am
Balance Sheet
Last Updated: December 4, 2025, 1:11 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 |
| Reserves | 7,780 | 9,768 | 12,484 | 12,179 | 12,489 | 13,941 | 15,516 | 17,558 | 19,129 | 23,203 | 28,171 | 33,466 | 35,930 |
| Borrowings | 4,477 | 4,314 | 3,352 | 4,918 | 5,071 | 3,838 | 2,210 | 3,031 | 3,384 | 1,347 | 2,002 | 4,677 | 5,854 |
| Other Liabilities | 3,563 | 4,290 | 4,408 | 4,474 | 4,706 | 4,557 | 5,414 | 5,915 | 7,149 | 7,576 | 8,523 | 9,797 | 12,505 |
| Total Liabilities | 15,906 | 18,457 | 20,330 | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 54,373 |
| Fixed Assets | 4,641 | 5,377 | 6,563 | 6,931 | 6,968 | 7,191 | 6,850 | 8,206 | 8,122 | 9,219 | 10,426 | 18,226 | 20,617 |
| CWIP | 639 | 529 | 772 | 3,324 | 3,470 | 2,934 | 1,535 | 1,565 | 1,293 | 1,030 | 1,419 | 2,466 | 1,997 |
| Investments | 1,067 | 2,248 | 3,833 | 2,110 | 2,298 | 2,587 | 2,678 | 2,212 | 2,616 | 4,986 | 4,930 | 4,051 | 4,701 |
| Other Assets | 9,559 | 10,303 | 9,162 | 9,290 | 9,612 | 9,707 | 12,160 | 14,605 | 17,715 | 16,974 | 22,004 | 23,280 | 27,058 |
| Total Assets | 15,906 | 18,457 | 20,330 | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 54,373 |
Below is a detailed analysis of the balance sheet data for Dr Reddys Laboratories Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 84.00 Cr.. The value appears strong and on an upward trend. It has increased from 83.00 Cr. (Mar 2025) to 84.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Sep 2025, the value is 35,930.00 Cr.. The value appears strong and on an upward trend. It has increased from 33,466.00 Cr. (Mar 2025) to 35,930.00 Cr., marking an increase of 2,464.00 Cr..
- For Borrowings, as of Sep 2025, the value is 5,854.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 4,677.00 Cr. (Mar 2025) to 5,854.00 Cr., marking an increase of 1,177.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 12,505.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 9,797.00 Cr. (Mar 2025) to 12,505.00 Cr., marking an increase of 2,708.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 54,373.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 48,023.00 Cr. (Mar 2025) to 54,373.00 Cr., marking an increase of 6,350.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 20,617.00 Cr.. The value appears strong and on an upward trend. It has increased from 18,226.00 Cr. (Mar 2025) to 20,617.00 Cr., marking an increase of 2,391.00 Cr..
- For CWIP, as of Sep 2025, the value is 1,997.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2,466.00 Cr. (Mar 2025) to 1,997.00 Cr., marking a decrease of 469.00 Cr..
- For Investments, as of Sep 2025, the value is 4,701.00 Cr.. The value appears strong and on an upward trend. It has increased from 4,051.00 Cr. (Mar 2025) to 4,701.00 Cr., marking an increase of 650.00 Cr..
- For Other Assets, as of Sep 2025, the value is 27,058.00 Cr.. The value appears strong and on an upward trend. It has increased from 23,280.00 Cr. (Mar 2025) to 27,058.00 Cr., marking an increase of 3,778.00 Cr..
- For Total Assets, as of Sep 2025, the value is 54,373.00 Cr.. The value appears strong and on an upward trend. It has increased from 48,023.00 Cr. (Mar 2025) to 54,373.00 Cr., marking an increase of 6,350.00 Cr..
Notably, the Reserves (35,930.00 Cr.) exceed the Borrowings (5,854.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -1.00 | -1.00 | 0.00 | -2.00 | -3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.00 | 5.00 | 4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 90 | 100 | 97 | 98 | 104 | 94 | 105 | 95 | 113 | 107 | 105 | 101 |
| Inventory Days | 271 | 248 | 248 | 282 | 263 | 273 | 230 | 273 | 250 | 232 | 283 | 260 |
| Days Payable | 100 | 84 | 88 | 104 | 121 | 111 | 100 | 109 | 111 | 108 | 116 | 97 |
| Cash Conversion Cycle | 261 | 264 | 257 | 275 | 246 | 256 | 235 | 259 | 252 | 231 | 271 | 264 |
| Working Capital Days | 32 | 26 | 34 | -14 | 39 | 65 | 59 | 57 | 61 | 84 | 118 | 69 |
| ROCE % | 25% | 22% | 19% | 9% | 8% | 13% | 11% | 16% | 14% | 27% | 27% | 23% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Parag Parikh Flexi Cap Fund | 13,125,545 | 1.27 | 1652.24 | 12,775,545 | 2025-12-15 01:10:08 | 2.74% |
| ICICI Prudential Value Fund | 11,845,856 | 2.47 | 1491.16 | N/A | N/A | N/A |
| Nippon India Large Cap Fund | 5,357,429 | 1.34 | 674.39 | N/A | N/A | N/A |
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 5,036,728 | 9.81 | 634.02 | 5,064,655 | 2025-12-15 01:10:08 | -0.55% |
| Nippon India Pharma Fund | 3,916,074 | 5.83 | 492.96 | 550,030 | 2025-09-18 02:15:08 | 611.97% |
| ICICI Prudential Large Cap Fund | 3,655,647 | 0.59 | 460.17 | N/A | N/A | N/A |
| Mirae Asset Large & Midcap Fund | 3,393,201 | 0.98 | 427.14 | 3,894,961 | 2025-12-15 01:10:08 | -12.88% |
| ICICI Prudential Balanced Advantage Fund | 3,177,174 | 0.57 | 399.94 | 4,412,174 | 2025-12-15 01:10:08 | -27.99% |
| ICICI Prudential Multi Asset Fund | 2,909,812 | 0.49 | 366.29 | N/A | N/A | N/A |
| Mirae Asset Large Cap Fund | 2,438,116 | 0.73 | 306.91 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Basic EPS (Rs.) | 67.89 | 335.22 | 271.47 | 131.57 | 117.67 |
| Diluted EPS (Rs.) | 67.79 | 334.59 | 270.90 | 131.21 | 117.34 |
| Cash EPS (Rs.) | 88.82 | 421.65 | 343.37 | 196.96 | 188.25 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 402.27 | 1693.93 | 1397.72 | 1154.59 | 1060.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 402.27 | 1693.93 | 1397.72 | 1154.59 | 1060.20 |
| Revenue From Operations / Share (Rs.) | 391.41 | 1679.32 | 1480.77 | 1294.78 | 1144.68 |
| PBDIT / Share (Rs.) | 115.64 | 529.22 | 444.45 | 255.53 | 250.08 |
| PBIT / Share (Rs.) | 95.21 | 441.09 | 369.41 | 185.51 | 176.23 |
| PBT / Share (Rs.) | 91.82 | 430.83 | 360.83 | 179.75 | 170.40 |
| Net Profit / Share (Rs.) | 68.39 | 333.52 | 268.32 | 126.94 | 114.40 |
| NP After MI And SOA / Share (Rs.) | 67.81 | 334.41 | 270.55 | 131.16 | 117.28 |
| PBDIT Margin (%) | 29.54 | 31.51 | 30.01 | 19.73 | 21.84 |
| PBIT Margin (%) | 24.32 | 26.26 | 24.94 | 14.32 | 15.39 |
| PBT Margin (%) | 23.45 | 25.65 | 24.36 | 13.88 | 14.88 |
| Net Profit Margin (%) | 17.47 | 19.86 | 18.12 | 9.80 | 9.99 |
| NP After MI And SOA Margin (%) | 17.32 | 19.91 | 18.27 | 10.12 | 10.24 |
| Return on Networth / Equity (%) | 16.85 | 19.74 | 19.35 | 11.35 | 11.06 |
| Return on Capital Employeed (%) | 21.81 | 25.13 | 25.95 | 15.44 | 15.84 |
| Return On Assets (%) | 11.44 | 14.35 | 13.96 | 7.33 | 7.33 |
| Long Term Debt / Equity (X) | 0.01 | 0.01 | 0.00 | 0.01 | 0.02 |
| Total Debt / Equity (X) | 0.12 | 0.05 | 0.04 | 0.16 | 0.15 |
| Asset Turnover Ratio (%) | 0.73 | 0.78 | 0.79 | 0.56 | 0.59 |
| Current Ratio (X) | 1.92 | 2.59 | 2.38 | 1.82 | 1.80 |
| Quick Ratio (X) | 1.37 | 1.92 | 1.81 | 1.30 | 1.24 |
| Inventory Turnover Ratio (X) | 4.85 | 0.80 | 0.84 | 0.85 | 1.03 |
| Dividend Payout Ratio (NP) (%) | 11.78 | 11.91 | 11.04 | 18.99 | 21.24 |
| Dividend Payout Ratio (CP) (%) | 9.05 | 9.43 | 8.64 | 12.38 | 13.03 |
| Earning Retention Ratio (%) | 88.22 | 88.09 | 88.96 | 81.01 | 78.76 |
| Cash Earning Retention Ratio (%) | 90.95 | 90.57 | 91.36 | 87.62 | 86.97 |
| Interest Coverage Ratio (X) | 34.09 | 51.59 | 51.85 | 44.39 | 42.90 |
| Interest Coverage Ratio (Post Tax) (X) | 21.16 | 33.51 | 32.30 | 23.05 | 20.62 |
| Enterprise Value (Cr.) | 97515.87 | 102592.50 | 76382.99 | 72310.86 | 75755.28 |
| EV / Net Operating Revenue (X) | 2.99 | 3.66 | 3.10 | 3.36 | 3.98 |
| EV / EBITDA (X) | 10.11 | 11.62 | 10.32 | 17.01 | 18.20 |
| MarketCap / Net Operating Revenue (X) | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 |
| Retention Ratios (%) | 88.21 | 88.08 | 88.95 | 81.00 | 78.75 |
| Price / BV (X) | 2.84 | 3.63 | 3.31 | 3.73 | 4.26 |
| Price / Net Operating Revenue (X) | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 |
| EarningsYield | 0.05 | 0.05 | 0.05 | 0.03 | 0.02 |
After reviewing the key financial ratios for Dr Reddys Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. It has decreased from 5.00 (Mar 24) to 1.00, marking a decrease of 4.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 67.89. This value is within the healthy range. It has decreased from 335.22 (Mar 24) to 67.89, marking a decrease of 267.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is 67.79. This value is within the healthy range. It has decreased from 334.59 (Mar 24) to 67.79, marking a decrease of 266.80.
- For Cash EPS (Rs.), as of Mar 25, the value is 88.82. This value is within the healthy range. It has decreased from 421.65 (Mar 24) to 88.82, marking a decrease of 332.83.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 402.27. It has decreased from 1,693.93 (Mar 24) to 402.27, marking a decrease of 1,291.66.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 402.27. It has decreased from 1,693.93 (Mar 24) to 402.27, marking a decrease of 1,291.66.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 391.41. It has decreased from 1,679.32 (Mar 24) to 391.41, marking a decrease of 1,287.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 115.64. This value is within the healthy range. It has decreased from 529.22 (Mar 24) to 115.64, marking a decrease of 413.58.
- For PBIT / Share (Rs.), as of Mar 25, the value is 95.21. This value is within the healthy range. It has decreased from 441.09 (Mar 24) to 95.21, marking a decrease of 345.88.
- For PBT / Share (Rs.), as of Mar 25, the value is 91.82. This value is within the healthy range. It has decreased from 430.83 (Mar 24) to 91.82, marking a decrease of 339.01.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 68.39. This value is within the healthy range. It has decreased from 333.52 (Mar 24) to 68.39, marking a decrease of 265.13.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 67.81. This value is within the healthy range. It has decreased from 334.41 (Mar 24) to 67.81, marking a decrease of 266.60.
- For PBDIT Margin (%), as of Mar 25, the value is 29.54. This value is within the healthy range. It has decreased from 31.51 (Mar 24) to 29.54, marking a decrease of 1.97.
- For PBIT Margin (%), as of Mar 25, the value is 24.32. This value exceeds the healthy maximum of 20. It has decreased from 26.26 (Mar 24) to 24.32, marking a decrease of 1.94.
- For PBT Margin (%), as of Mar 25, the value is 23.45. This value is within the healthy range. It has decreased from 25.65 (Mar 24) to 23.45, marking a decrease of 2.20.
- For Net Profit Margin (%), as of Mar 25, the value is 17.47. This value exceeds the healthy maximum of 10. It has decreased from 19.86 (Mar 24) to 17.47, marking a decrease of 2.39.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.32. This value is within the healthy range. It has decreased from 19.91 (Mar 24) to 17.32, marking a decrease of 2.59.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.85. This value is within the healthy range. It has decreased from 19.74 (Mar 24) to 16.85, marking a decrease of 2.89.
- For Return on Capital Employeed (%), as of Mar 25, the value is 21.81. This value is within the healthy range. It has decreased from 25.13 (Mar 24) to 21.81, marking a decrease of 3.32.
- For Return On Assets (%), as of Mar 25, the value is 11.44. This value is within the healthy range. It has decreased from 14.35 (Mar 24) to 11.44, marking a decrease of 2.91.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.12. This value is within the healthy range. It has increased from 0.05 (Mar 24) to 0.12, marking an increase of 0.07.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.78 (Mar 24) to 0.73, marking a decrease of 0.05.
- For Current Ratio (X), as of Mar 25, the value is 1.92. This value is within the healthy range. It has decreased from 2.59 (Mar 24) to 1.92, marking a decrease of 0.67.
- For Quick Ratio (X), as of Mar 25, the value is 1.37. This value is within the healthy range. It has decreased from 1.92 (Mar 24) to 1.37, marking a decrease of 0.55.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.85. This value is within the healthy range. It has increased from 0.80 (Mar 24) to 4.85, marking an increase of 4.05.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 11.78. This value is below the healthy minimum of 20. It has decreased from 11.91 (Mar 24) to 11.78, marking a decrease of 0.13.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 9.05. This value is below the healthy minimum of 20. It has decreased from 9.43 (Mar 24) to 9.05, marking a decrease of 0.38.
- For Earning Retention Ratio (%), as of Mar 25, the value is 88.22. This value exceeds the healthy maximum of 70. It has increased from 88.09 (Mar 24) to 88.22, marking an increase of 0.13.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 90.95. This value exceeds the healthy maximum of 70. It has increased from 90.57 (Mar 24) to 90.95, marking an increase of 0.38.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 34.09. This value is within the healthy range. It has decreased from 51.59 (Mar 24) to 34.09, marking a decrease of 17.50.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.16. This value is within the healthy range. It has decreased from 33.51 (Mar 24) to 21.16, marking a decrease of 12.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 97,515.87. It has decreased from 102,592.50 (Mar 24) to 97,515.87, marking a decrease of 5,076.63.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.99. This value is within the healthy range. It has decreased from 3.66 (Mar 24) to 2.99, marking a decrease of 0.67.
- For EV / EBITDA (X), as of Mar 25, the value is 10.11. This value is within the healthy range. It has decreased from 11.62 (Mar 24) to 10.11, marking a decrease of 1.51.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.92. This value is within the healthy range. It has decreased from 3.67 (Mar 24) to 2.92, marking a decrease of 0.75.
- For Retention Ratios (%), as of Mar 25, the value is 88.21. This value exceeds the healthy maximum of 70. It has increased from 88.08 (Mar 24) to 88.21, marking an increase of 0.13.
- For Price / BV (X), as of Mar 25, the value is 2.84. This value is within the healthy range. It has decreased from 3.63 (Mar 24) to 2.84, marking a decrease of 0.79.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.92. This value is within the healthy range. It has decreased from 3.67 (Mar 24) to 2.92, marking a decrease of 0.75.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Reddys Laboratories Ltd:
- Net Profit Margin: 17.47%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 21.81% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.85% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 21.16
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.37
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.4 (Industry average Stock P/E: 53.57)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.12
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.47%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 8-2-337, Road No. 3, Hyderabad Telangana 500034 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. K Satish Reddy | Chairman |
| Mr. G V Prasad | Co-Chairman & Manag. Director |
| Dr. Claudio Albrecht | Independent Director |
| Mr. Leo Puri | Independent Director |
| Ms. Shikha Sharma | Independent Director |
| Mr. Sanjiv Mehta | Independent Director |
| Mr. Arun M Kumar | Independent Director |
| Dr. K P Krishnan | Independent Director |
| Ms. Penny Wan | Independent Director |
| Dr. Alpna Seth | Independent Director |
FAQ
What is the intrinsic value of Dr Reddys Laboratories Ltd?
Dr Reddys Laboratories Ltd's intrinsic value (as of 08 January 2026) is ₹1089.56 which is 9.73% lower the current market price of ₹1,207.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,00,732 Cr. market cap, FY2025-2026 high/low of ₹1,386/1,020, reserves of ₹35,930 Cr, and liabilities of ₹54,373 Cr.
What is the Market Cap of Dr Reddys Laboratories Ltd?
The Market Cap of Dr Reddys Laboratories Ltd is 1,00,732 Cr..
What is the current Stock Price of Dr Reddys Laboratories Ltd as on 08 January 2026?
The current stock price of Dr Reddys Laboratories Ltd as on 08 January 2026 is ₹1,207.
What is the High / Low of Dr Reddys Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Dr Reddys Laboratories Ltd stocks is ₹1,386/1,020.
What is the Stock P/E of Dr Reddys Laboratories Ltd?
The Stock P/E of Dr Reddys Laboratories Ltd is 17.4.
What is the Book Value of Dr Reddys Laboratories Ltd?
The Book Value of Dr Reddys Laboratories Ltd is 432.
What is the Dividend Yield of Dr Reddys Laboratories Ltd?
The Dividend Yield of Dr Reddys Laboratories Ltd is 0.66 %.
What is the ROCE of Dr Reddys Laboratories Ltd?
The ROCE of Dr Reddys Laboratories Ltd is 22.7 %.
What is the ROE of Dr Reddys Laboratories Ltd?
The ROE of Dr Reddys Laboratories Ltd is 18.0 %.
What is the Face Value of Dr Reddys Laboratories Ltd?
The Face Value of Dr Reddys Laboratories Ltd is 1.00.